Genmab A/ S stock (DK0010272202): antibody specialist with strong oncology focus and US partnerships

Genmab A/S, the Danish antibody specialist listed in Copenhagen and on Nasdaq, has built its growth story around oncology products like Darzalex in partnership with US pharma groups. This deep dive explains the business model, key markets, and why the stock matters for Nordic and international investors.

Genmab A/S has developed into one of the most visible Nordic biotechnology names, with a clear focus on antibody-based therapeutics for cancer and other serious diseases. The company is headquartered in Copenhagen and its stock is listed on Nasdaq Copenhagen, with an additional listing on Nasdaq in the United States, giving investors in Denmark and abroad direct access to its equity. For local investors in the company’s home market, Genmab A/S is an important healthcare representative within the Danish stock universe and a way to participate in the global development of innovative oncology treatments.

A core element of the Genmab A/S story is its expertise in antibody discovery and development. Over the years, the company has created several antibody platforms and partnered with large pharmaceutical companies to bring new medicines to patients. One of the most prominent examples is the multiple myeloma treatment marketed under the brand name Darzalex, which was developed by Genmab A/S and is commercialized globally in collaboration with a major US-based pharmaceutical partner. Through such arrangements, Genmab A/S typically receives milestone payments, royalties on sales, and sometimes co-promotion rights, which together form a key part of its revenue model.

As of: 26.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Genmab
• Sector/industry: Biotechnology / biopharmaceuticals (oncology focus)
• Headquarters/country: Copenhagen, Denmark
• Core markets: North America, Europe, and selected markets in Asia-Pacific
• Key revenue drivers: Antibody-based oncology medicines, royalties, milestone payments, and collaboration income
• Home exchange/listing venue: Nasdaq Copenhagen (GEN) and Nasdaq in the US
• Trading currency: Primarily Danish krone (DKK) in Copenhagen; US dollar (USD) for the US listing

Genmab A/S: core business model

The core business model of Genmab A/S revolves around discovering, developing, and commercializing antibody therapeutics, particularly in oncology. The company builds its pipeline through internal research and development, focusing on differentiated antibody technologies that can address unmet medical needs. Genmab A/S often advances drug candidates through early and mid-stage clinical trials before entering into partnerships with larger pharmaceutical companies that provide global commercialization infrastructure and broader clinical development capabilities.

This partnership-based approach is central to how Genmab A/S generates value for shareholders. Instead of building a fully integrated global sales and marketing organization, the company leverages the networks of established, large-cap pharma partners. In return, Genmab A/S receives upfront payments when deals are signed, development and regulatory milestone payments as compounds progress through clinical stages and gain approvals, and ongoing royalties based on net sales once products reach the market. This structure allows Genmab A/S to manage risk and capital intensity while maintaining exposure to the commercial success of its key products.

Another element of the business model is selective co-commercialization in specific territories. In some partnerships, Genmab A/S takes a more active role in commercial activities, especially in markets where it seeks to build direct relationships with treating physicians and healthcare systems. This can increase operational complexity, but it also provides an opportunity for higher margins and more direct market insight. For investors in Denmark, the balance between pure royalty income and more integrated commercial efforts is an important aspect when interpreting the company’s long-term strategy.

Genmab A/S also invests in proprietary technology platforms that support the design of next-generation antibodies. These platforms are used both for the company’s own pipeline and in collaboration projects where partners gain access to the technology for specified targets or indications. In such cases, Genmab A/S can derive revenue from licensing fees and collaborative R&D payments, in addition to potential downstream royalties if new products reach the market. This layered approach means that the company’s income streams can be diversified across several programs and partnerships, reducing dependence on any single asset.

The cost structure of Genmab A/S is largely determined by its R&D spending, which typically accounts for a substantial portion of operating expenses. Early-stage discovery, preclinical work, and clinical trials in oncology are resource-intensive, and the company regularly allocates significant capital to these activities. For investors, this translates into a trade-off between current profitability and the potential for future growth driven by pipeline advancement. Over time, successful commercialization of antibody products can improve margins, but ongoing investment in innovation remains central to Genmab A/S’s competitive position in the global biopharmaceutical landscape.

Main revenue and product drivers for Genmab A/S

Revenue at Genmab A/S is primarily driven by a combination of royalties from marketed products, milestone payments from partners, and, to a lesser extent, direct product sales in selected markets. Among these, royalties on oncology therapies based on Genmab A/S’s antibody technology are generally the most visible component for investors. As prescriptions and market penetration for these therapies expand, royalty income can scale materially without the company having to build extensive commercial infrastructure on its own, which can positively affect operating leverage.

One of the best-known products linked to Genmab A/S is the multiple myeloma treatment based on the antibody daratumumab, widely marketed under the brand Darzalex. This therapy has become an important option for patients with multiple myeloma and has been introduced in various treatment settings. The underlying antibody was created by Genmab A/S and is developed and commercialized in partnership with a major global pharmaceutical company. Genmab A/S typically earns tiered royalties on global net sales, which makes the performance of this drug franchise a key metric followed by investors and analysts.

In addition to Darzalex, Genmab A/S has other antibody programs that have reached the market or are progressing through late-stage clinical trials. These include therapies targeting different cancer indications and immune-related diseases. Each approved product or successfully partnered late-stage asset adds another potential royalty or profit-sharing stream. For shareholders, the breadth of this portfolio can offer diversification, as not all candidates will achieve the same level of commercial success, but a group of products together can generate a more stable revenue base over time.

Milestone payments constitute another meaningful revenue driver. As partnered drug candidates move through clinical phases and obtain regulatory approvals in major markets such as the United States and the European Union, Genmab A/S may receive predefined payments. These can be irregular and tied to specific events, which sometimes leads to quarter-to-quarter volatility in reported revenue. However, when viewed over several years, cumulative milestones from a broad pipeline can represent a substantial source of funding for ongoing R&D and potential shareholder returns.

Beyond product-related income, Genmab A/S also generates revenue from research collaborations and technology licensing. In these arrangements, partners gain access to the company’s antibody platforms and scientific expertise, while Genmab A/S receives research funding and the potential for success-based payments. Although these deals may be smaller in absolute terms than major oncology product partnerships, they contribute to the overall revenue mix and help sustain the innovation engine. For Danish investors, this combination of royalties, milestones, and collaborative income provides a multi-layered financial profile that is somewhat different from traditional pharmaceutical companies with large in-house sales forces.

From a regional perspective, a significant portion of Genmab A/S’s economic exposure is linked to the United States and other major international pharmaceutical markets where oncology therapies can command premium pricing and high volume. At the same time, being headquartered and listed in Denmark means that the company remains closely tied to the Nordic life sciences ecosystem, including local research institutions and clinical trial networks. This combination of a Danish base with global revenue drivers is one reason why Genmab A/S is often seen as a flagship biotech name within the Copenhagen market.

Conclusion

Genmab A/S stock offers investors exposure to a Danish-based biotechnology company whose value creation is closely linked to antibody innovation, especially in oncology. The combination of a strong scientific platform, established partnerships with large pharmaceutical players, and a growing portfolio of marketed and late-stage assets has turned the company into a central healthcare name on Nasdaq Copenhagen with an additional presence on the US Nasdaq market. For investors in its home market, Genmab A/S also represents participation in the broader Nordic life sciences cluster, while its revenue streams predominantly arise from global oncology markets.

Looking ahead, the company’s performance will depend on the continued success of key products such as the daratumumab franchise, the progression of its pipeline candidates, and the ability to sign new partnerships that monetize its technology platforms. At the same time, high R&D spending and the inherent risks of drug development remain structural features of the investment case. For retail investors and institutional participants in Denmark and beyond, monitoring clinical milestones, regulatory decisions, and collaboration announcements will remain essential to understanding the risk–reward profile of Genmab A/S stock over the medium to long term.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.